Citi raised the firm’s price target on Tandem Diabetes to $31 from $25 and keeps a Neutral rating on the shares. The analyst updated the company’s model to reflect reflect slightly elevated interest expense as well as the $30M share repurchase. The firm cites the “constructive MedTech tape” and recent management commentary for the higher price target.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on TNDM:
- Tandem Diabetes announces private placement of $250M in convertible senior notes
- Tandem Diabetes (NASDAQ:TNDM): Investors Look to Innovation to Drive the Stock Higher
- Tandem Diabetes sees Q1 revenue $175M, consensus $186.09M
- Tandem Diabetes sees FY24 non-GAAP revenue roughly $850M, consensus $842.49M
- Tandem Diabetes reports Q4 adjusted EPS (46c), consensus (25c)
